The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and utility of the custom RNA-seq for the identification of therapeutic targets and diagnostic biomarkers in glioma.
 
Masamichi Takahashi
Honoraria - Fujifilm; Johnson & Johnson/Janssen
 
Shinji Kohsaka
Research Funding - Boehringer Ingelheim; Chordia Therapeutics; CMIC; Eisai; Konica Minolta; TransThera Biosciences
Patents, Royalties, Other Intellectual Property - Konica Minolta (Inst)
 
Koichi Ichimura
Honoraria - Chugai Pharma; Congrès; Convex
Research Funding - Daiichi Sankyo Co.,Ltd.; EPS Corporation; Leica Biosystems; Riken Genesis; SRL Diagnostics; Sumitomo Dainippon Pharma Co., Ltd.; Therabiopharma Inc.
Other Relationship - Idorsia
 
Hiroyuki Mano
Employment - CureGene; CureGene (I)
Leadership - CureGene
Research Funding - Ambry Genetics; Daiichi Sankyo; Konica Minolta; Ono Pharmaceutical; Ono Pharmaceutical; PFDeNA
Patents, Royalties, Other Intellectual Property - Probe design for gene fusion detection (Inst)
 
Yoshitaka Narita
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Novocure; Ono Pharmaceutical; Sumitomo Dainippon Pharma Oncology
Consulting or Advisory Role - Dainippon Sumitomo Pharma
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Ohara Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Stella pharma (Inst); Taiho Pharmaceutical (Inst)